Editing Ai Drug Adverse (section)

== <span style="color: #FFFFFF;">Understanding</span> ==
Pharmacovigilance faces three core data challenges:
# '''spontaneous underreporting''' — only 6–10% of adverse reactions are ever reported, creating massive selection bias;
# '''data heterogeneity''' — reports use inconsistent terminology, varying detail levels, and multiple languages;
# '''confounding''' — patients taking a drug may have the disease that caused the adverse event, making causal attribution difficult.

'''EHR mining for ADE detection''': Large EHR databases (CPRD in UK, Optum in US, VA CDW) contain millions of patient records with drug prescriptions and outcome data. ML and pharmacoepidemiology methods (self-controlled case series, prescription sequence symmetry analysis) detect unexpected drug-outcome associations. Stanford's PURPLE and FDA's Sentinel System apply these approaches systematically.

'''NLP for spontaneous report processing''': FDA FAERS receives thousands of reports daily as unstructured text. NLP pipelines extract structured drug-ADE pairs:
# entity recognition identifies drugs and medical concepts;
# relation extraction identifies which drug caused which event;
# negation handling distinguishes "developed rash" from "no rash developed";
# MedDRA coding maps free text to standard terminology. FDA's ARIA project and academic systems automate FAERS processing.

'''Social media signal detection''': Patients discuss medication side effects on Twitter, Reddit (/r/medication, /r/askdocs), DailyStrength, and PatientsLikeMe before reporting to FAERS. NLP analysis of these discussions can surface signals earlier. Challenges: slang ("pilled", "brain zaps" for SSRI discontinuation), spam, and high noise ratio. Studies show social media signals precede FAERS signals by 3–6 months for some drugs.

'''Computational DDI prediction''': With thousands of approved drugs and millions of possible pairs, experimental testing of all drug-drug interactions is impossible. ML models predict DDI risk from: drug molecular features, protein binding profiles, pharmacokinetic parameters, and known interaction databases (DrugBank, STITCH). Graph neural networks on drug-protein interaction networks achieve AUC >0.9 for DDI prediction.
</div>

<div style="background-color: #8B0000; color: #FFFFFF; padding: 20px; border-radius: 8px; margin-bottom: 15px;">